查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1875759

抗毒素：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

Antivenom - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 129 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024年全球抗毒素市場規模估計為10.41億美元，預計到2031年將達到13.83億美元，2025年至2031年的複合年成長率為4.2%。

本報告對近期有關抗蛇毒血清跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組的關稅調整和國際戰略措施進行了全面評估。

抗蛇毒血清，也稱為抗蛇毒免疫球蛋白，是一種抗體製劑，用於治療某些毒蛇咬傷和昆蟲叮咬。它僅建議用於嚴重或高風險的毒液感染。所需的抗蛇毒血清劑量因蛇種而異，給藥方式為注射。

受技術創新驅動

突破性的人工智慧設計的抗毒素蛋白：人工智慧設計的微型抗毒素蛋白（如 HT-101）將研發週期從 6-12 個月縮短至 2 週，將單劑量成本降低至 20 美元以下（而傳統血清的成本為 150-300 美元），並顯著提高穩定性（在 40°C 下保持 6 個月）。

先進的生產流程：傳統的動物性血清正擴大被高純度製程所取代，例如採用層析法純化等技術，從而降低了過敏反應的發生率（例如，破傷風抗毒素反應減少了 40% 以上）。

合成蛋白質替代：人工智慧設計的蛋白質可以中和多種毒素（例如，眼鏡蛇三指毒素+鍍銀蛇神經毒素），預計到 2030 年將佔據 30% 以上的市場佔有率。

製劑創新：正在開發凍乾粉末注射器，以支持現場緊急治療。

政策利多：在中國，抗蛇毒血清現已納入甲類醫療保險，加速了在基層醫院的應用。全球採購合約也已將產能轉移到印度和中國（成本降低了40%）。

技術創新（人工智慧設計的蛋白質+純化製程）將降低成本並提高療效，政策支援將加速新興市場的採用，而從多價血清到合成蛋白質的轉變將重塑產業格局。

本報告旨在按地區/國家、類型和應用對全球抗蛇毒血清市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

抗毒素市場規模、估算和預測以銷售量（千管瓶）和收入（百萬美元）為單位呈現，以2024年為基準年，並包含2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定抗毒素業務/成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • CSL
  • Merck
  • BTG
  • Pfizer
  • Haffkine Bio-Pharmaceutical
  • Rare Disease Therapeutics
  • Flynn Pharma
  • Vins Bioproducts
  • Bharat Serums and Vaccines
  • Serum Biotech
  • MicroPharm

按類型分類的細分市場

  • 多價抗蛇毒血清
  • 單價抗蛇毒血清

應用領域

  • 非營利組織
  • 醫院和診所

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Antivenom was estimated to be worth US$ 1041 million in 2024 and is forecast to a readjusted size of US$ 1383 million by 2031 with a CAGR of 4.2% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Antivenom cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.

Technological innovation drives

AI design breakthrough in anti-toxin proteins: AI-designed micro-sized anti-toxin proteins (such as HT-101) can shorten the research and development cycle from 6-12 months to 2 weeks, reduce the cost of a single dose to below $20 (compared to $150-300 for traditional serum), and significantly improve stability (with 98% activity maintained at 40°C for 6 months).

Production process upgrade: Traditional animal-derived serum is accelerating its transition to a high-purity process, reducing the rate of allergic reactions through techniques such as chromatography purification (for example, the reaction rate of tetanus antitoxin decreased by 40%+).

Synthetic protein substitution: AI-designed proteins can neutralize multiple toxins (such as cobra three-finger toxin + silver ring snake neurotoxin), with a market share expected to exceed 30% by 2030.

Formulation innovation: Development of freeze-dried powder syringes is underway, supporting on-site emergency treatment.

Policy benefits: China has included anti-venom serum in Class A medical insurance with full reimbursement, accelerating the popularization in grassroots hospitals; Global procurement agreements have promoted the transfer of production capacity to India and China (cost reduction by 40%).

Technological iteration (AI-designed proteins + purification process) drives cost reduction and improvement in efficacy, policy support accelerates coverage in emerging markets, and the upgrade from multivalent serum to synthetic protein will reshape the industry landscape.

This report aims to provide a comprehensive presentation of the global market for Antivenom, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Antivenom by region & country, by Type, and by Application.

The Antivenom market size, estimations, and forecasts are provided in terms of sales volume (K Vials) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antivenom.

Market Segmentation

By Company

  • CSL
  • Merck
  • BTG
  • Pfizer
  • Haffkine Bio-Pharmaceutical
  • Rare Disease Therapeutics
  • Flynn Pharma
  • Vins Bioproducts
  • Bharat Serums and Vaccines
  • Serum Biotech
  • MicroPharm

Segment by Type

  • Polyvalent antivenom
  • Monovalent antivenom

Segment by Application

  • Non-profit Institutions
  • Hospitals and Clinic

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Antivenom manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Antivenom in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Antivenom in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Antivenom Product Introduction
  • 1.2 Global Antivenom Market Size Forecast
    • 1.2.1 Global Antivenom Sales Value (2020-2031)
    • 1.2.2 Global Antivenom Sales Volume (2020-2031)
    • 1.2.3 Global Antivenom Sales Price (2020-2031)
  • 1.3 Antivenom Market Trends & Drivers
    • 1.3.1 Antivenom Industry Trends
    • 1.3.2 Antivenom Market Drivers & Opportunity
    • 1.3.3 Antivenom Market Challenges
    • 1.3.4 Antivenom Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Antivenom Players Revenue Ranking (2024)
  • 2.2 Global Antivenom Revenue by Company (2020-2025)
  • 2.3 Global Antivenom Players Sales Volume Ranking (2024)
  • 2.4 Global Antivenom Sales Volume by Company Players (2020-2025)
  • 2.5 Global Antivenom Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Antivenom Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Antivenom Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Antivenom
  • 2.9 Antivenom Market Competitive Analysis
    • 2.9.1 Antivenom Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Antivenom Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antivenom as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Polyvalent antivenom
    • 3.1.2 Monovalent antivenom
  • 3.2 Global Antivenom Sales Value by Type
    • 3.2.1 Global Antivenom Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Antivenom Sales Value, by Type (2020-2031)
    • 3.2.3 Global Antivenom Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Antivenom Sales Volume by Type
    • 3.3.1 Global Antivenom Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Antivenom Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Antivenom Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Antivenom Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Non-profit Institutions
    • 4.1.2 Hospitals and Clinic
  • 4.2 Global Antivenom Sales Value by Application
    • 4.2.1 Global Antivenom Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Antivenom Sales Value, by Application (2020-2031)
    • 4.2.3 Global Antivenom Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Antivenom Sales Volume by Application
    • 4.3.1 Global Antivenom Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Antivenom Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Antivenom Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Antivenom Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Antivenom Sales Value by Region
    • 5.1.1 Global Antivenom Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Antivenom Sales Value by Region (2020-2025)
    • 5.1.3 Global Antivenom Sales Value by Region (2026-2031)
    • 5.1.4 Global Antivenom Sales Value by Region (%), (2020-2031)
  • 5.2 Global Antivenom Sales Volume by Region
    • 5.2.1 Global Antivenom Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Antivenom Sales Volume by Region (2020-2025)
    • 5.2.3 Global Antivenom Sales Volume by Region (2026-2031)
    • 5.2.4 Global Antivenom Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Antivenom Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Antivenom Sales Value, 2020-2031
    • 5.4.2 North America Antivenom Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Antivenom Sales Value, 2020-2031
    • 5.5.2 Europe Antivenom Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Antivenom Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Antivenom Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Antivenom Sales Value, 2020-2031
    • 5.7.2 South America Antivenom Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Antivenom Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Antivenom Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Antivenom Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Antivenom Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Antivenom Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Antivenom Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Antivenom Sales Value, 2020-2031
    • 6.3.2 United States Antivenom Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Antivenom Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Antivenom Sales Value, 2020-2031
    • 6.4.2 Europe Antivenom Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Antivenom Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Antivenom Sales Value, 2020-2031
    • 6.5.2 China Antivenom Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Antivenom Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Antivenom Sales Value, 2020-2031
    • 6.6.2 Japan Antivenom Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Antivenom Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Antivenom Sales Value, 2020-2031
    • 6.7.2 South Korea Antivenom Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Antivenom Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Antivenom Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Antivenom Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Antivenom Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Antivenom Sales Value, 2020-2031
    • 6.9.2 India Antivenom Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Antivenom Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 CSL
    • 7.1.1 CSL Company Information
    • 7.1.2 CSL Introduction and Business Overview
    • 7.1.3 CSL Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 CSL Antivenom Product Offerings
    • 7.1.5 CSL Recent Development
  • 7.2 Merck
    • 7.2.1 Merck Company Information
    • 7.2.2 Merck Introduction and Business Overview
    • 7.2.3 Merck Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Merck Antivenom Product Offerings
    • 7.2.5 Merck Recent Development
  • 7.3 BTG
    • 7.3.1 BTG Company Information
    • 7.3.2 BTG Introduction and Business Overview
    • 7.3.3 BTG Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 BTG Antivenom Product Offerings
    • 7.3.5 BTG Recent Development
  • 7.4 Pfizer
    • 7.4.1 Pfizer Company Information
    • 7.4.2 Pfizer Introduction and Business Overview
    • 7.4.3 Pfizer Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Pfizer Antivenom Product Offerings
    • 7.4.5 Pfizer Recent Development
  • 7.5 Haffkine Bio-Pharmaceutical
    • 7.5.1 Haffkine Bio-Pharmaceutical Company Information
    • 7.5.2 Haffkine Bio-Pharmaceutical Introduction and Business Overview
    • 7.5.3 Haffkine Bio-Pharmaceutical Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Haffkine Bio-Pharmaceutical Antivenom Product Offerings
    • 7.5.5 Haffkine Bio-Pharmaceutical Recent Development
  • 7.6 Rare Disease Therapeutics
    • 7.6.1 Rare Disease Therapeutics Company Information
    • 7.6.2 Rare Disease Therapeutics Introduction and Business Overview
    • 7.6.3 Rare Disease Therapeutics Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Rare Disease Therapeutics Antivenom Product Offerings
    • 7.6.5 Rare Disease Therapeutics Recent Development
  • 7.7 Flynn Pharma
    • 7.7.1 Flynn Pharma Company Information
    • 7.7.2 Flynn Pharma Introduction and Business Overview
    • 7.7.3 Flynn Pharma Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Flynn Pharma Antivenom Product Offerings
    • 7.7.5 Flynn Pharma Recent Development
  • 7.8 Vins Bioproducts
    • 7.8.1 Vins Bioproducts Company Information
    • 7.8.2 Vins Bioproducts Introduction and Business Overview
    • 7.8.3 Vins Bioproducts Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Vins Bioproducts Antivenom Product Offerings
    • 7.8.5 Vins Bioproducts Recent Development
  • 7.9 Bharat Serums and Vaccines
    • 7.9.1 Bharat Serums and Vaccines Company Information
    • 7.9.2 Bharat Serums and Vaccines Introduction and Business Overview
    • 7.9.3 Bharat Serums and Vaccines Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Bharat Serums and Vaccines Antivenom Product Offerings
    • 7.9.5 Bharat Serums and Vaccines Recent Development
  • 7.10 Serum Biotech
    • 7.10.1 Serum Biotech Company Information
    • 7.10.2 Serum Biotech Introduction and Business Overview
    • 7.10.3 Serum Biotech Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Serum Biotech Antivenom Product Offerings
    • 7.10.5 Serum Biotech Recent Development
  • 7.11 MicroPharm
    • 7.11.1 MicroPharm Company Information
    • 7.11.2 MicroPharm Introduction and Business Overview
    • 7.11.3 MicroPharm Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 MicroPharm Antivenom Product Offerings
    • 7.11.5 MicroPharm Recent Development

8 Industry Chain Analysis

  • 8.1 Antivenom Industrial Chain
  • 8.2 Antivenom Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Antivenom Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Antivenom Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Antivenom Market Trends
  • Table 2. Antivenom Market Drivers & Opportunity
  • Table 3. Antivenom Market Challenges
  • Table 4. Antivenom Market Restraints
  • Table 5. Global Antivenom Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Antivenom Revenue Market Share by Company (2020-2025)
  • Table 7. Global Antivenom Sales Volume by Company (2020-2025) & (K Vials)
  • Table 8. Global Antivenom Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Antivenom Price by Company (2020-2025) & (USD/Vial)
  • Table 10. Key Manufacturers Antivenom Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Antivenom Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Antivenom
  • Table 13. Global Antivenom Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antivenom as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Antivenom Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Antivenom Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Antivenom Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Antivenom Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Antivenom Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Antivenom Sales Volume by Type: 2020 VS 2024 VS 2031 (K Vials)
  • Table 22. Global Antivenom Sales Volume by Type (2020-2025) & (K Vials)
  • Table 23. Global Antivenom Sales Volume by Type (2026-2031) & (K Vials)
  • Table 24. Global Antivenom Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Antivenom Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Antivenom Price by Type (2020-2025) & (USD/Vial)
  • Table 27. Global Antivenom Price by Type (2026-2031) & (USD/Vial)
  • Table 28. Global Antivenom Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Antivenom Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Antivenom Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Antivenom Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Antivenom Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Antivenom Sales Volume by Application: 2020 VS 2024 VS 2031 (K Vials)
  • Table 34. Global Antivenom Sales Volume by Application (2020-2025) & (K Vials)
  • Table 35. Global Antivenom Sales Volume by Application (2026-2031) & (K Vials)
  • Table 36. Global Antivenom Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Antivenom Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Antivenom Price by Application (2020-2025) & (USD/Vial)
  • Table 39. Global Antivenom Price by Application (2026-2031) & (USD/Vial)
  • Table 40. Global Antivenom Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Antivenom Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Antivenom Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Antivenom Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Antivenom Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Antivenom Sales Volume by Region (K Vials): 2020 VS 2024 VS 2031
  • Table 46. Global Antivenom Sales Volume by Region (2020-2025) & (K Vials)
  • Table 47. Global Antivenom Sales Volume by Region (2026-2031) & (K Vials)
  • Table 48. Global Antivenom Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Antivenom Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Antivenom Average Price by Region (2020-2025) & (USD/Vial)
  • Table 51. Global Antivenom Average Price by Region (2026-2031) & (USD/Vial)
  • Table 52. Key Countries/Regions Antivenom Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Antivenom Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Antivenom Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Antivenom Sales Volume, (2020-2025) & (K Vials)
  • Table 56. Key Countries/Regions Antivenom Sales Volume, (2026-2031) & (K Vials)
  • Table 57. CSL Company Information
  • Table 58. CSL Introduction and Business Overview
  • Table 59. CSL Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 60. CSL Antivenom Product Offerings
  • Table 61. CSL Recent Development
  • Table 62. Merck Company Information
  • Table 63. Merck Introduction and Business Overview
  • Table 64. Merck Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 65. Merck Antivenom Product Offerings
  • Table 66. Merck Recent Development
  • Table 67. BTG Company Information
  • Table 68. BTG Introduction and Business Overview
  • Table 69. BTG Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 70. BTG Antivenom Product Offerings
  • Table 71. BTG Recent Development
  • Table 72. Pfizer Company Information
  • Table 73. Pfizer Introduction and Business Overview
  • Table 74. Pfizer Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 75. Pfizer Antivenom Product Offerings
  • Table 76. Pfizer Recent Development
  • Table 77. Haffkine Bio-Pharmaceutical Company Information
  • Table 78. Haffkine Bio-Pharmaceutical Introduction and Business Overview
  • Table 79. Haffkine Bio-Pharmaceutical Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 80. Haffkine Bio-Pharmaceutical Antivenom Product Offerings
  • Table 81. Haffkine Bio-Pharmaceutical Recent Development
  • Table 82. Rare Disease Therapeutics Company Information
  • Table 83. Rare Disease Therapeutics Introduction and Business Overview
  • Table 84. Rare Disease Therapeutics Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 85. Rare Disease Therapeutics Antivenom Product Offerings
  • Table 86. Rare Disease Therapeutics Recent Development
  • Table 87. Flynn Pharma Company Information
  • Table 88. Flynn Pharma Introduction and Business Overview
  • Table 89. Flynn Pharma Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 90. Flynn Pharma Antivenom Product Offerings
  • Table 91. Flynn Pharma Recent Development
  • Table 92. Vins Bioproducts Company Information
  • Table 93. Vins Bioproducts Introduction and Business Overview
  • Table 94. Vins Bioproducts Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 95. Vins Bioproducts Antivenom Product Offerings
  • Table 96. Vins Bioproducts Recent Development
  • Table 97. Bharat Serums and Vaccines Company Information
  • Table 98. Bharat Serums and Vaccines Introduction and Business Overview
  • Table 99. Bharat Serums and Vaccines Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 100. Bharat Serums and Vaccines Antivenom Product Offerings
  • Table 101. Bharat Serums and Vaccines Recent Development
  • Table 102. Serum Biotech Company Information
  • Table 103. Serum Biotech Introduction and Business Overview
  • Table 104. Serum Biotech Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 105. Serum Biotech Antivenom Product Offerings
  • Table 106. Serum Biotech Recent Development
  • Table 107. MicroPharm Company Information
  • Table 108. MicroPharm Introduction and Business Overview
  • Table 109. MicroPharm Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)
  • Table 110. MicroPharm Antivenom Product Offerings
  • Table 111. MicroPharm Recent Development
  • Table 112. Key Raw Materials Lists
  • Table 113. Raw Materials Key Suppliers Lists
  • Table 114. Antivenom Downstream Customers
  • Table 115. Antivenom Distributors List
  • Table 116. Research Programs/Design for This Report
  • Table 117. Key Data Information from Secondary Sources
  • Table 118. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Antivenom Product Picture
  • Figure 2. Global Antivenom Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Antivenom Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Antivenom Sales Volume (2020-2031) & (K Vials)
  • Figure 5. Global Antivenom Sales Price (2020-2031) & (USD/Vial)
  • Figure 6. Antivenom Report Years Considered
  • Figure 7. Global Antivenom Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Antivenom Players Sales Volume Ranking (2024) & (K Vials)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Antivenom Revenue in 2024
  • Figure 10. Antivenom Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Polyvalent antivenom Picture
  • Figure 12. Monovalent antivenom Picture
  • Figure 13. Global Antivenom Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Antivenom Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Antivenom Sales Volume by Type (2020 VS 2024 VS 2031) & (K Vials)
  • Figure 16. Global Antivenom Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Antivenom Price by Type (2020-2031) & (USD/Vial)
  • Figure 18. Product Picture of Non-profit Institutions
  • Figure 19. Product Picture of Hospitals and Clinic
  • Figure 20. Global Antivenom Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Antivenom Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. Global Antivenom Sales Volume by Application (2020 VS 2024 VS 2031) & (K Vials)
  • Figure 23. Global Antivenom Sales Volume Market Share by Application, 2024 & 2031
  • Figure 24. Global Antivenom Price by Application (2020-2031) & (USD/Vial)
  • Figure 25. North America Antivenom Sales Value (2020-2031) & (US$ Million)
  • Figure 26. North America Antivenom Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Europe Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Europe Antivenom Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Asia Pacific Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Asia Pacific Antivenom Sales Value by Region (%), 2024 VS 2031
  • Figure 31. South America Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. South America Antivenom Sales Value by Country (%), 2024 VS 2031
  • Figure 33. Middle East & Africa Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Middle East & Africa Antivenom Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Key Countries/Regions Antivenom Sales Value (%), (2020-2031)
  • Figure 36. Key Countries/Regions Antivenom Sales Volume (%), (2020-2031)
  • Figure 37. United States Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. United States Antivenom Sales Value by Type (%), 2024 VS 2031
  • Figure 39. United States Antivenom Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Europe Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Europe Antivenom Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Europe Antivenom Sales Value by Application (%), 2024 VS 2031
  • Figure 43. China Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. China Antivenom Sales Value by Type (%), 2024 VS 2031
  • Figure 45. China Antivenom Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Japan Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Japan Antivenom Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Japan Antivenom Sales Value by Application (%), 2024 VS 2031
  • Figure 49. South Korea Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. South Korea Antivenom Sales Value by Type (%), 2024 VS 2031
  • Figure 51. South Korea Antivenom Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Southeast Asia Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. Southeast Asia Antivenom Sales Value by Type (%), 2024 VS 2031
  • Figure 54. Southeast Asia Antivenom Sales Value by Application (%), 2024 VS 2031
  • Figure 55. India Antivenom Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. India Antivenom Sales Value by Type (%), 2024 VS 2031
  • Figure 57. India Antivenom Sales Value by Application (%), 2024 VS 2031
  • Figure 58. Antivenom Industrial Chain
  • Figure 59. Antivenom Manufacturing Cost Structure
  • Figure 60. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 61. Bottom-up and Top-down Approaches for This Report
  • Figure 62. Data Triangulation
  • Figure 63. Key Executives Interviewed